Inactivation of (1-->3)-beta-D-glucan in mice.
Intraperitoneally or intravenously administered (1-->3)-beta-D-glucan remained in the liver and spleen, for a long time without major structural changes, but the priming activity to lipopolysaccharide (LPS)-triggered tumor necrosis factor-alpha (TNF-alpha) production was reduced more quickly. The relationship between the deposited glucan contents and the antitumor activity was examined by comparing kinetics of the activity using solid form Sarcoma 180 tumor in ICR mice. We used three kinds of soluble glucans, sonifilan (SPG), grifolan (GRN), and SSG, and a particulate glucan, zymosan (ZYM). These were administered 5 weeks before (-5W) the tumor inoculation and the tumor weight was compared 5 weeks after the inoculation. Compared with the activity of those administered at the optimum timing, all of the glucans reduced the activity about 5 fold, although significant activity still remained, especially in the case of SPG. Five weeks after intraperitoneal (SPG, GRN, SSG) or intravenous (ZYM) administration of the glucans, all were found in the liver and spleen in significant quantities. These facts strongly suggested that the activity of the glucan was reduced not only because of chemical/physical degradation but also a certain physiological inactivation mechanism.
Miura
T
T
Tokyo University of Pharmacy and Life Science, Japan.
Ohno
N
N
Suda
M
M
Miura
N N
NN
Shimada
S
S
Yadomae
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001219:Aspartate Aminotransferases; D001806:Blood Urea Nitrogen; D005936:Glucans / Q000378:metabolism* / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000378:metabolism; D013154:Spleen / Q000378:metabolism; D047071:beta-Glucans
D000970:Antineoplastic Agents; D005936:Glucans; D047071:beta-Glucans; C033363:beta-1,3-glucan; D001219:Aspartate Aminotransferases